Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dipyridamole + rubidium-82 is a combination used in myocardial perfusion imaging, specifically for the noninvasive diagnosis of coronary artery disease (CAD) using positron emission tomography (PET). Dipyridamole acts as a pharmacologic vasodilator, inducing hyperemia by increasing coronary blood flow. Rubidium-82 is a radioactive potassium analog radiopharmaceutical that is rapidly taken up by viable myocardium proportional to blood flow via sodium-potassium ATPase pumps. Areas with reduced perfusion or infarction show decreased uptake on PET imaging. This combination allows assessment of myocardial perfusion under pharmacologic stress conditions, especially in patients unable to undergo exercise-based stress testing[2][6][8]. Rubidium-82 is supplied as a generator product (e.g., Cardiogen-82 Generator, Ruby-Fill Generator) and has a very short half-life (~1.27 minutes)[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dipyridamole + rubidium-82.